New England Compounding Pharmacy Inc. Files Bankruptcy

New England Compounding Pharmacy Inc., the Massachusetts pharmaceutical company blamed for a nationwide meningitis outbreak, filed for bankruptcy protection to deal with lawsuits filed against it.

More than 30 people died and 490 were injured after the company shipped fungus-tainted drugs to customers throughout the U.S., according to the Centers for Disease Control and Prevention. The company plans to establish a fund under Chapter 11 of the U.S. Bankruptcy Code to compensate individuals and families affected by the outbreak.

The Framingham-based company listed both assets and debt of $1 million to $10 million in Chapter 11 documents filed yesterday in U.S. Bankruptcy Court in Boston.

New England Compounding’s “goal is to provide a greater, quicker, fairer payout to its creditors than they could achieve through piecemeal litigation,” the company said yesterday in a statement.

Under bankruptcy law, all litigation against a company or individual who seeks protection is put on hold while the case is pending. A judge can grant a request to allow the claims to proceed outside bankruptcy court in some instances.

The case is In re New England Compounding Pharmacy Inc., 12-19882, U.S. Bankruptcy Court, District of Massachusetts (Boston).

To contact the reporter on this story: Dawn McCarty in Wilmington at

To contact the editor responsible for this story: John Pickering at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.